Abstract 442P
Background
CDK4/6 inhibitors added to hormone therapy (CDKi-HT) is the standard first-line (1L) treatment for patients with HR+/HER2- advanced breast cancer (ABC). After CDKi-HT, treatment strategies are associated with shorter progression-free survival (PFS), and therapeutic strategies are usually tailored to clinical factors and predictive biomarkers. Our aim was to explore prognostic factors in the second-line (2L) treatment setting and determine clinical factors associated with treatment efficacy.
Methods
Retrospective cohort of HR+/HER2- ABC patients, from 17 public and private facilities in Argentina. Patients were included if started 2L treatment between November 2015 and October 2022. Clinical factors associated with treatment decisions were evaluated with t and chi-square tests. Kaplan-Meier method was used for survival analysis. Cox regression tests were applied to explore prognostic factors. p<0,05 was considered statistically significant.
Results
280 patients were analyzed (Mean age 52.4+/-14, 57% postmenopausal). 98.5% received CDKi-HT in the 1L setting (med. PFS 17.8m, CI95% 8.1-28.4). Among the 240 patients with evaluable data, 39.2% received chemotherapy (CT) for the 2L setting and 53.7% received hormone therapy with or without other agents. With a median follow-up of 26 months, med. 2L-PFS was 6.6 months (CI 95% 5.8-7.6). After applying multivariate analysis, menopausal status (adj. HR 0.65 CI95% 0.44-0.98; p=0.038) and primary sample Ki67 (adj. HR 2.37 CI95% 1.14-4.9, p=0.02) were associated with 2L-PFS. An interaction was observed between selected treatment agents and menopausal status (p=0.015). In patients that did not receive CT, Median 2L-PFS was 4.66 (CI95% 4.06-6.03) and 8.7 (CI95 7-11.16) months for premenopausal and postmenopausal patients respectively (p=0.0006).
Conclusions
Real-world evidence is relevant to obtain further information regarding prognostic and predictive factors. Treatment selection should be carefully individualized in patients that experienced disease progression after CDKi-HT. The implications of our results should be carefully analyzed incorporating the experiences of other collaborative efforts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
338P - Breast cancer follow-up: A population-based cohort study
Presenter: Serena Di Cosimo
Session: Poster session 03
339P - An online mindfulness-based stress-reduction (MBSR) intervention for breast cancer (BC) survivors: A randomized trial
Presenter: Misael Salazar-Alejo
Session: Poster session 03
340P - Novel application of spatial analyses to investigate environmental factors and hormone receptor-positive breast cancer
Presenter: Alexandra Thomas
Session: Poster session 03
341P - Impact of environmental temperature on clinical outcomes of early-stage breast cancer (BC)
Presenter: Arya Mariam Roy
Session: Poster session 03
342P - Fertility preservation in young breast cancer patients: Patient's knowledge and perception
Presenter: Zeineb Naimi
Session: Poster session 03
343P - Modulation of the immune system (ImS) during moderate physical activity (mPA) in breast cancer (BC) patients (pts) treated with neoadjuvant chemotherapy (NACT)
Presenter: Ornella Garrone
Session: Poster session 03
344P - Epidemiological analysis and overall survival of female breast cancer in a developing middle eastern country over 18 years
Presenter: Mahmoud Abunasser
Session: Poster session 03
345P - The effect of early post-operative exercise on shoulder function in breast cancer patients: A randomised controlled trial
Presenter: Jihee Min
Session: Poster session 03
348P - Long-term opioid use following treatment of localized breast cancer: A real-world analysis
Presenter: Ayelet Shai
Session: Poster session 03